Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center, randomized, double-blind, placebo-controlled clinical trial for the safety, tolerability and efficacy of ularitide in cirrhosis patients with refractory ascites

Next Previous
Trial Profile

Single-center, randomized, double-blind, placebo-controlled clinical trial for the safety, tolerability and efficacy of ularitide in cirrhosis patients with refractory ascites

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ularitide (Primary)
  • Indications Ascites; Liver cirrhosis
  • Focus Therapeutic Use
  • Acronyms ULA04

Most Recent Events

  • 16 May 2023 Status changed from recruiting to discontinued.
  • 12 Jan 2023 The trial has been discontinued in Denmark, according to European Clinical Trials Database record.
  • 18 May 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Jan 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top